CNTF Implants for CNGB3 Achromatopsia

NCT01648452 | Completed Phase 1 Results DMC

• 2 other identifiers: 12016712-EI-0167
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Background:

• Achromatopsia is an inherited condition that causes vision loss because cells in the retina do not work properly. It causes loss of acuity, sensitivity to light, and loss of color vision. There are no effective treatments for achromatopsia.
• Four genes currently are known to cause achromatopsia. One of these, the cyclic nucleotide-gated channel beta 3 (CNGB3) gene, is the cause in about 50 percent of people.
• CNTF is a natural chemical found in the body that promotes survival and function of nerve cells. CNTF has been shown to be effective in treating retinal disease in animals and can slow vision loss.
• CNTF has also been studied in over 250 people with retinal disease other than achromatopsia. In these studies, a CNTF implant was placed into the eye during a simple surgery. The implant releases CNTF inside the eye, near the retina. These studies suggested that a CNTF implant might help vision in some eye diseases. Objectives:
• To learn whether a CNTF implant is safe for people with CNGB3 achromatopsia.
• To learn whether CNTF can improve visual acuity or color vision, and whether it may reduce sensitivity to light in people with CNGB3 achromatopsia. Eligibility: You may be able to take part in this study if you:
• Are at least 18 years old.
• Test positive for mutations in the CNGB3 gene and have no mutations in another achromatopsia gene.
• Have 20/100 vision or worse in at least one eye.
• Are not pregnant or nursing. Design:
• To determine if you can take part, we will ask about your medical history and do a physical examination and an eye examination. Blood and urine samples will be taken.
• This study requires 11 visits to the National Eye Institute over 3 years.
• One visit will be for the implant surgery. The implant will be placed in one eye only.
• Study visits will take place 1 day after implant surgery, and again 1 week later and 1 month, 3 months, 6 months, 1 year, 1.5 years and 3 years later. These visits will help us evaluate the safety and benefit of the implant on your eye.
• At the 3 year visit, you can choose to keep the CNTF implant in your eye, or you can have us remove it.

Conditions

Eye Disease; Achromatopsia

Keywords

Achromatopsia; Ciliary Neurotrophic Factor; CNTF

Outcome Measures

Primary Outcomes (4)

• Number of Adverse Events at Six Months Post-Implantation

  The primary outcome is the total number of adverse events reported within six months post-implantation.

  Day 1, Week 1, Week 4, Week 12, Week 24 post-implantation

• Number of Severe Adverse Events at Six Months Post-Implantation

  The number of severe adverse events reported within six months post-implantation.

  Day 1, Week 1, Week 4, Week 12, Week 24 post-implantation

• Number of Ocular Adverse Events at Six Months Post-Implantation

  The number of eye-related adverse events reported within six months post-implantation.

  Day 1, Week 1, Week 4, Week 12, Week 24 post-implantation

• Number of Non-Ocular Adverse Events at Six Months Post-Implantation

  The number of non eye-related adverse events reported within six months post-implantation.

  Day 1, Week 1, Week 4, Week 12, Week 24 post-implantation

Secondary Outcomes (10)

• Number of Adverse Events at All Time Points Post-Implantation

  Day 1, Week 1, Week 4, Week 12, Week 24, Week 52, Week 78, Week 156 post-implantation

• Number of Severe Adverse Events at All Time Points Post-Implantation

  Day 1, Week 1, Week 4, Week 12, Week 24, Week 52, Week 78, Week 156 post-implantation

• Number of Ocular Adverse Events at All Time Points Post-Implantation

  Day 1, Week 1, Week 4, Week 12, Week 24, Week 52, Week 78, Week 156 post-implantation

• Number of Non-Ocular Adverse Events at All Time Points Post-Implantation

  Day 1, Week 1, Week 4, Week 12, Week 24, Week 52, Week 78, Week 156 post-implantation

• Number of Participants Who Experienced an Improvement in Visual Acuity of Greater Than 0.3 logMAR (Logarithm of the Minimum Angle of Resolution) Post-Implantation in the Study Eye.

  Day 1, Week 1, Week 4, Week 12, Week 24, Week 52, Week 78, Week 156 post-implantation

Study Arms (1)

NT-501 CNTF-releasing implant

EXPERIMENTAL

Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline

Biological: NT-501 CNTF-releasing implant

Interventions

NT-501 CNTF-releasing implant BIOLOGICAL

20 ng/day released into the eye

NT-501 CNTF-releasing implant

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be 18 years of age or older.
• Participant must carry two alleles for CNGB3 gene mutations and no cyclic nucleotide-gated channel alpha 3 (CNGA3) sequence variations as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
• Participant must understand and sign the protocol informed consent.
• Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse, or must agree to use contraception during the first six months following implantation. Acceptable forms of contraception include:hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, or surgical sterilization (tubal ligation).

You may not qualify if:

• Participant has a history of other ocular disease likely to contribute significantly to visual loss (e.g., optic neuropathy, glaucoma, uveitis, or other retinal disease).
• Participant is judged by the investigator as not sufficiently healthy to safely undergo ophthalmic surgery.
• Participant is on anticoagulant therapy that cannot be safely stopped peri-operatively at the implant procedure. Patients on warfarin will always be excluded. Patients on aspirin will be asked to stop the medication at least seven days prior to the surgery (when not contraindicated by the underlying medical condition). The stoppage period for other anticoagulant medications is based on the best clinical judgment of the investigator surgeon and is variable depending on the patient's medical condition and the type of medication.
• Participant has had diagnosis or treatment of a malignancy (excluding non-melanoma skin cancer) within the previous five years.
• Participant has received investigational treatment in another clinical study related to an ocular condition in the last six months.
• Participant is pregnant, lactating or planning to become pregnant in the first six months following implantation.
• Study Eye Eligibility Criteria:
• The study eye must have a best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity letterscore of ≤ 53 (i.e., ≤ 20/100). The visual acuity from the first baseline visit (Baseline 1) will be used for eligibility determination in case of a change in visual acuity at the second baseline visit (Baseline 2).
• The study eye has a choroidal nevus or ocular neoplasm with potential risk for malignant transformation.
• The study eye is judged by the investigator, based on history or examination findings, as high-risk for retinal detachment, vitreous hemorrhage, infection, or uveitis.
• The study eye has lens, cornea, or other media opacities precluding adequate visualization and testing of the retina.
• The study eye has undergone intraocular surgery within 12 months prior to enrollment.
• Study Eye Selection Criteria in Cases of Bilateral Disease:
• As this is a genetic condition that usually affects both eyes to a similar degree, if both eyes of a participant meet the study eye eligibility criteria and have comparable visual acuity, the study eye will be selected at the investigator's medical judgment after consultation with the participant.
• In case of an eye with lower visual acuity, that eye will be selected as the study eye.

Sponsors & Collaborators

• National Eye Institute (NEI): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• Kohl S, Baumann B, Broghammer M, Jagle H, Sieving P, Kellner U, Spegal R, Anastasi M, Zrenner E, Sharpe LT, Wissinger B. Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet. 2000 Sep 1;9(14):2107-16. doi: 10.1093/hmg/9.14.2107.

  PMID: 10958649 BACKGROUND

• Wissinger B, Gamer D, Jagle H, Giorda R, Marx T, Mayer S, Tippmann S, Broghammer M, Jurklies B, Rosenberg T, Jacobson SG, Sener EC, Tatlipinar S, Hoyng CB, Castellan C, Bitoun P, Andreasson S, Rudolph G, Kellner U, Lorenz B, Wolff G, Verellen-Dumoulin C, Schwartz M, Cremers FP, Apfelstedt-Sylla E, Zrenner E, Salati R, Sharpe LT, Kohl S. CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet. 2001 Oct;69(4):722-37. doi: 10.1086/323613. Epub 2001 Aug 30.

  PMID: 11536077 BACKGROUND

• Kohl S, Baumann B, Rosenberg T, Kellner U, Lorenz B, Vadala M, Jacobson SG, Wissinger B. Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet. 2002 Aug;71(2):422-5. doi: 10.1086/341835. Epub 2002 Jun 20.

  PMID: 12077706 BACKGROUND

• Zein WM, Jeffrey BG, Wiley HE, Turriff AE, Tumminia SJ, Tao W, Bush RA, Marangoni D, Wen R, Wei LL, Sieving PA. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci. 2014 Sep 9;55(10):6301-8. doi: 10.1167/iovs.14-14860.

  PMID: 25205868 RESULT

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Eye Diseases; Color Vision Defects

Condition Hierarchy (Ancestors)

Vision Disorders; Sensation Disorders; Neurologic Manifestations; Nervous System Diseases; Cone Dystrophy; Eye Diseases, Hereditary; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Paul A Sieving, MD, PhD
• Organization: National Eye Institute

ps261o@nih.gov

301-496-2234

Study Officials

• Paul A Sieving, MD, PhD

  National Eye Institute (NEI)

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 20, 2012
• First Posted: July 24, 2012
• Study Start: July 1, 2012
• Primary Completion: March 1, 2013
• Study Completion: October 1, 2015
• Last Updated: November 21, 2016
• Results First Posted: February 25, 2014

Record last verified: 2016-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)